ARMP

Armata Pharmaceuticals Inc. [ARMP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ARMP Stock Summary

Top 10 Correlated Stocks

ARMP

In the News

ARMP Financial details

Company Rating
-
Market Cap
117.48M
Income
-72.19M
Revenue
4.53M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
66
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.84
Forward P/E
-
PEG
-0.22
P/S
-
P/B
-9.32
P/C
-
P/FCF
-2.1
Quick Ratio
1.48
Current Ratio
1.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2
EPS next Y
-
EPS next Q
-
EPS this Y
76.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
24.73%
EPS Q/Q
-36.05%
-
-
-
-
SMA20
-5.24%
SMA50
-10.36%
SMA100
-12.33%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
-384%
ROC
-0.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.07-5.26
52W High
-57.8%
52W Low
+111%
RSI
56.79
Rel Volume
1.31
Avg Volume
16.33K
Volume
21.41K
Perf Week
6.03%
Perf Month
1.93%
Perf Quarter
-12.08%
Perf Half Y
-7.86%
-
-
-
-
Beta
0.701
-
-
Volatility
0.06%, 0.07%
Prev Close
4.98%
Price
2.11
Change
6.03%

Something similar

Top by Market Cap
CMC.DE
VTSAX
TL0.DE
ABEC.DE
AMZ.DE
Same Sector
MOR
CALT
ASP.TO
KOAN
MESO
Top Correlated Stocks
USEG
ARL
Similar Market Cap
IBHC
1621.HK
HIPS
LEE
SAL

Company Profile

Healthcare Biotechnology
  • Volume Average 16.33K
  • Market Capitalization 117.48M
  • Employee 66
  • CEO Dr. Deborah L. Birx M.D.
  • Headquarters Marina del Rey,CA,US
  • IPO Date 1994-05-20
  • Website https://www.armatapharma.com

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.